Physician profile
Justin Richard Boike
NPI 1497014294
$24,201.67
in general payments reported to CMS, 2019-2025
9 companies · $23K in 2025
The $23K reported for 2025 was more than what 77% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $270 · 2023: $19.58 · 2024: $176 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $3,630 · Food and Beverage: $751 · Travel and Lodging: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,672.31 |
| Consulting Fee | $3,630.00 |
| Food and Beverage | $751.29 |
| Travel and Lodging | $698.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18,842.08 | 2022-2025 | Wegovy |
| W. L. Gore & Associates, INC. | $3,661.64 | 2022-2025 | Gore Viatorr Tips Endoprosthesis With Controlled Expansion, Gore Viatorr Tips Endoprosthesis |
| Fujifilm Healthcare Americas Corporation | $1,131.00 | 2021 | |
| Cook Medical LLC | $168.25 | 2022 | |
| Mallinckrodt Hospital Products INC. | $161.53 | 2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $142.31 | 2025 | Voquezna |
| Gilead Sciences, INC. | $60.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.32 | 2023-2024 | Xifaxan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Boike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.